Amarin Corporation PLC (NASDAQ:AMRN - Get Free Report)'s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $10.52 and traded as high as $12.74. Amarin shares last traded at $12.60, with a volume of 62,500 shares trading hands.
Wall Street Analyst Weigh In
Several research firms recently weighed in on AMRN. The Goldman Sachs Group lifted their price objective on shares of Amarin from $7.00 to $12.00 and gave the stock a "sell" rating in a research note on Wednesday. Wall Street Zen upgraded Amarin from a "sell" rating to a "hold" rating in a report on Thursday, May 8th.
Get Our Latest Report on AMRN
Amarin Stock Up 0.9%
The company's fifty day moving average price is $11.39 and its two-hundred day moving average price is $10.56. The company has a market cap of $335.29 million, a price-to-earnings ratio of -4.40 and a beta of 0.71.
Amarin (NASDAQ:AMRN - Get Free Report) last released its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02. Amarin had a negative return on equity of 17.21% and a negative net margin of 41.07%. On average, equities research analysts predict that Amarin Corporation PLC will post -0.15 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Amarin
Several hedge funds have recently modified their holdings of the stock. Acadian Asset Management LLC boosted its position in Amarin by 112.3% during the first quarter. Acadian Asset Management LLC now owns 3,791,515 shares of the biopharmaceutical company's stock valued at $1,685,000 after purchasing an additional 2,005,713 shares during the last quarter. Jones Financial Companies Lllp raised its position in Amarin by 449,522.1% during the first quarter. Jones Financial Companies Lllp now owns 1,811,977 shares of the biopharmaceutical company's stock worth $815,000 after acquiring an additional 1,811,574 shares in the last quarter. Stonepine Capital Management LLC raised its position in Amarin by 470.3% during the first quarter. Stonepine Capital Management LLC now owns 651,614 shares of the biopharmaceutical company's stock worth $293,000 after acquiring an additional 537,357 shares in the last quarter. LCM Capital Management Inc lifted its stake in Amarin by 2.4% in the first quarter. LCM Capital Management Inc now owns 858,259 shares of the biopharmaceutical company's stock valued at $385,000 after acquiring an additional 20,000 shares during the last quarter. Finally, Banque Cantonale Vaudoise bought a new position in shares of Amarin in the 1st quarter valued at about $25,000. Institutional investors own 22.25% of the company's stock.
About Amarin
(
Get Free Report)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Featured Stories
Before you consider Amarin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amarin wasn't on the list.
While Amarin currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
